Prelude Highlights Continued Strength of Discovery Engine
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at...
Source: globenewswire.com
Phase 1 Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Phase 1 Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Phase 1 Study Today - Breaking & Trending Today
FDA Clears Investigational New Drug Application for TCR-NK Cell Therapy in Multiple Myeloma
The FDA has issued a ‘safe to proceed’ for the investigational new drug application enabling a phase 1 study evaluating NY-ESO-1 TCR/IL-15 NK, a first-in-class engineered T-cell receptor natural killer cell therapy for patients with relapsed/refractory multiple myeloma.
Source: onclive.com
PHE855 Continues to Show High, Durable Responses in R/R Multiple Myeloma
Now that positive phase 1 results have been reported for PHE855, a phase 2 study of PHE855 is currently underway in patients with relapsed and refractory multiple myeloma.
Source: targetedonc.com
IO-108 Demonstrates Safety and Efficacy in Advanced Solid Tumors
Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.
Source: onclive.com
Pharma Stock News: Skye Bioscience (OTCQB: SKYE) Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsion
Pharma Stock News: Skye Bioscience (OTCQB: SKYE) Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsion
Source: investorideas.com